Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.769 EUR | +2.26% | -2.04% | +78.84% |
Mar. 11 | Sensorion: study results in hearing loss | CF |
Mar. 11 | Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation | CI |
Business Summary
Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates.
Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation.
Sensorion has entered into a strategic collaboration with Institut Pasteur. It has two gene therapy programs, at preclinical stage, aimed at correcting hereditary forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene.
Number of employees: 57
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nawal Ouzren
CEO | Chief Executive Officer | 45 | 17-04-11 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | Dec. 10 |
Géraldine Honnet
CTO | Chief Tech/Sci/R&D Officer | - | 20-02-17 |
Noémie Djokovic
IRC | Investor Relations Contact | - | - |
Judith Laredo
PRN | Corporate Officer/Principal | - | - |
Valerie Salentey
LAW | General Counsel | - | 20-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Cédric Moreau
BRD | Director/Board Member | - | - |
Khalil Barrage
CHM | Chairman | 59 | - |
John Furey
BRD | Director/Board Member | 59 | 19-08-31 |
Florian Reinaud
BRD | Director/Board Member | 51 | - |
Director/Board Member | - | 15-03-08 | |
Aniz Girach
BRD | Director/Board Member | 56 | 22-01-02 |
Julien Miara
BRD | Director/Board Member | - | - |
Nawal Ouzren
CEO | Chief Executive Officer | 45 | 17-04-11 |
Director/Board Member | 50 | Jan. 23 | |
Natalie Berner
BRD | Director/Board Member | 34 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 187,080,794 | 79,138,558 ( 42.30 %) | 0 | 42.30 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
SENSORION 0.05% | 144,811 | 0.05% | 142,604 $ |
Company contact information
Sensorion SA
375, rue du Professeur Joseph Blayac
34080, Montpellier
+33 4 67 20 77 30
http://www.sensorion.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+78.84% | 224M | |
+9.57% | 45.97B | |
+52.73% | 43.93B | |
+7.44% | 42.34B | |
-8.78% | 28.27B | |
+18.40% | 27.18B | |
-21.68% | 19.44B | |
+14.76% | 13.83B | |
+32.35% | 12.4B | |
+4.93% | 11.45B |
- Stock
- Equities
- Stock Sensorion - Euronext Paris
- Company Sensorion